Online first
Current issue
Archive
Special Issues
About the Journal
Publication Ethics
Anti-Plagiarism system
Instructions for Authors
Instructions for Reviewers
Editorial Board
Editorial Office
Contact
Reviewers
All Reviewers
2024
2023
2022
2021
2020
2019
2018
2017
2016
General Data Protection Regulation (RODO)
RESEARCH PAPER
The impact of type 2 diabetes on selected clinical parameters and serological markers in patients with EBV-related oropharyngeal cancer
1
Aldent Center of Dentistry and Implantology, Lublin, Poland
2
Department of Virology with Viral Diagnostics Laboratory, Medical University, Lublin, Poland
3
Faculty of Human Sciences, University of Economics and Innovation, Lublin, Poland
Corresponding author
Marcin Koleśnik
Department of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, Lublin, Poland
Department of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, Lublin, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Diabetes can lead to many complications and may also increase the risk of malignant tumours. Numerous studies have shown that diabetes not only increases the incidence, but also affects the prognosis of many cancers, including those of the head and neck. The aim of the study was to assess the possible impact of diabetes on the clinical course of EBV-related oropharyngeal cancer. For this purpose, the frequency of G and TN features was analyzed among diabetic EBV-related oropharyngeal cancer patients compared with those without diabetes. The study also took into account the duration of diabetes (in years) and the level of anti-EBV antibodies.
Material and methods:
The study included a total of 115 patients diagnosed and histologically confirmed oropharyngeal squamous cell carcinoma (OPSCC). The research used tumour tissue samples taken during surgery and sera. EBV DNA was detected by PCR in the tissue and anti-EBV antibodies were detected in the serum (ELISA test).
Results:
Poorly differentiated tumours (G3) and more advanced clinical stages (T3 – T4) as well as more involved lymph nodes (N) were observed in diabetic patients. The frequency of the mentioned clinical parameters depended on the duration of diabetes. The level of anti-EBNA and anti-EBVCA antibodies was significantly lower in the group of patients with diabetes (both in IgA and IgG classes). Patients suffering from diabetes for over 6 years had significantly lower levels of tested antibodies. The obtained results encourage further, in-depth research in this area.
Conclusions:
More advanced stages of EBV-related OPSCC and lower levels of anti-EBV antibodies are observed in diabetic patients.
Diabetes can lead to many complications and may also increase the risk of malignant tumours. Numerous studies have shown that diabetes not only increases the incidence, but also affects the prognosis of many cancers, including those of the head and neck. The aim of the study was to assess the possible impact of diabetes on the clinical course of EBV-related oropharyngeal cancer. For this purpose, the frequency of G and TN features was analyzed among diabetic EBV-related oropharyngeal cancer patients compared with those without diabetes. The study also took into account the duration of diabetes (in years) and the level of anti-EBV antibodies.
Material and methods:
The study included a total of 115 patients diagnosed and histologically confirmed oropharyngeal squamous cell carcinoma (OPSCC). The research used tumour tissue samples taken during surgery and sera. EBV DNA was detected by PCR in the tissue and anti-EBV antibodies were detected in the serum (ELISA test).
Results:
Poorly differentiated tumours (G3) and more advanced clinical stages (T3 – T4) as well as more involved lymph nodes (N) were observed in diabetic patients. The frequency of the mentioned clinical parameters depended on the duration of diabetes. The level of anti-EBNA and anti-EBVCA antibodies was significantly lower in the group of patients with diabetes (both in IgA and IgG classes). Patients suffering from diabetes for over 6 years had significantly lower levels of tested antibodies. The obtained results encourage further, in-depth research in this area.
Conclusions:
More advanced stages of EBV-related OPSCC and lower levels of anti-EBV antibodies are observed in diabetic patients.
ACKNOWLEDGEMENTS
The authors express their thanks to Prof. dr. Kamal Morhed, director of the Head and Neck Cancer Otolaryngology Clinic at the Casemiro Pułaski University in Radom, Poland, for sharing and assisting with the collection of clinical material.
REFERENCES (23)
1.
Zapatka M, Borozan I, Brewer DS, et al. The landscape of viral associations in human cancers. Nat Genet. 2020;52:320–330.
2.
Carpén T, Syrjanen S, Jouhi L, et al. Epstein-Barr Virus (EBV) and Polyomaviruses Are Detectable in Oropharyngeal Cancer and EBV May Have Prognostic Impact. Cancer Immunol Immunother. 2020;69:1615–1626.
3.
de Lima MAP, Silva ÁDL, do Nascimento Filho ACS, et al. Epstein-Barr Virus-Associated Carcinoma of the Larynx: A Systematic Review with Meta-Analysis. Pathogens. 2021;10(11):1429.
4.
Holt RIG, Cockram CS, Ma RCW, Luk AOY. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. Diabetologia. 2024;67(7):1168–1180.
5.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes. Res Clin Pract. 2017;128:40–50.
6.
IDF Diabetes Atlas10 th edition 2021; Available online: https://diabetesatlas.org/data..., (accessed on 14 February 2025).
7.
Zatońska K, Basiak-Rasała A, Różańska D, et al. Changes in diabetes prevalence and corresponding risk factors – findings from 3- and 6-year follow-up of PURE Poland cohort study. BMC Public Health. 2020;20:843.
8.
Abu-Ashour W, Twells L, Valcour J, et al. The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies. BMJ Open Diabetes Res Care. 2017;5:e000336.
9.
Rajsfus BF, Mohana-Borges R, Allonso D. Diabetogenic viruses: linking viruses to diabetes mellitus. Heliyon. 2023;9(4):e15021.
10.
Dworzański J, Drop B, Kliszczewska E, Strycharz-Dudziak M, Polz-Dacewicz M. Prevalence of Epstein-Barr virus, human papillomavirus, cytomegalovirus and herpes simplex virus type 1 in patients with diabetes mellitus type 2 in south-eastern Poland. PLoS ONE. 2019;14(9):e0222607.
11.
AJCC Cancer Staging Manual, 8th ed; Amin MB, Edge SB, Greene FL, et al, editors. New York, NY, USA: Springer; 2017.
12.
WHO Classification of Tumours Editorial Board. WHO classification of tumours series. In: Head and Neck Tumours, 5th ed. Inter Agency Res Cancer: Lyon, France, 2022; 9.
13.
Chen Y, Wu F, Saito E, et al. Association Between Type 2 Diabetes and Risk of Cancer Mortality: A Pooled Analysis of Over 771,000 Individuals in the Asia Cohort Consortium. Diabetol. 2017; 60:1022–32.
14.
Zhu B, Qu S, The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms. Front Endocrinol. 2022;13:800995.
15.
Viedma-Rodríguez R, Martínez-Hernández MG, Martínez-Torres DI, et al. Epithelial mesenchymal transition and progression of breastcancer promoted by diabetes mellitus in mice are associated with increased expression of glycolytic and proteolytic enzymes. Horm Cancer. 2020;1:170– 81.
16.
Guo G, Fu M, Wei S, Chen R. Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis. Onco Targets Ther. 2018;11:1193–1201.
17.
Peng X-S, Xie G-F, Qiu W-Z, et al. Type 2 Diabetic Mellitus Is a Risk Factor for Nasopharyngeal Carcinoma: A 1:2 Matched Case–Control Study. PLoS ONE. 2016;11(10):e0165131.
18.
Midorikawa S, Mizukami H, Kudoh K, et al. Diabetes can increase the prevalence of EBV infection and worsen the prognosis of nasopharyngeal carcinoma. Pathology. 2024;56(1):65–74.
19.
Zhang J, Jia L, Lin W, Epstein-Barr virus encoded latent membrane protein-1 upregulates glucose transporter-1 transcription via the mTORC1/NF-kappa B signaling pathways. J Virol. 2017;9:e02168.
20.
Zhou T, Hu Z, Yang S, et al. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. J Diabetes Res. 2018;7457269.
21.
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2020;16(5):442–449.
22.
Daryabor G, Atashzar MR, Kabelitz D. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582.
23.
Ali H, Alterki A, Sindhu S, et al. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 MRNA COVID-19 Vaccination. Front Immunol. 2021;12:752233.
Share
RELATED ARTICLE
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2025 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
